Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chances Upped Supreme Court Hears Amgen/Sandoz Biosimilars Suit

Executive Summary

While an invitation for the top US government litigator to weigh in on Amgen Inc. v. Sandoz Inc. has prolonged the Supreme Court's decision on whether it will take up the case – creating a certain amount of limbo for the biosimilars marketplace – the request demonstrates the justices appear to be taking the matter seriously, upping the chances they may hear oral arguments potentially next spring.

You may also be interested in...



Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?

With the FDA giving an overwhelmingly positive review of Sandoz Inc.'s application for its biosimilar version of Enbrel (etanercept), which is sold in the US by Amgen Inc., the product appears to be headed to the US market – pending a likely blessing from the agency's advisory panel, which is meeting on July 13. But Sandoz must still get past litigation and convince prescribers and patients its etanercept biosimilar provides value over Enbrel.

Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?

With the FDA giving an overwhelmingly positive review of Sandoz Inc.'s application for its biosimilar version of Enbrel (etanercept), which is sold in the US by Amgen Inc., the product appears to be headed to the US market – pending a likely blessing from the agency's advisory panel, which is meeting on July 13. But Sandoz must still get past litigation and convince prescribers and patients its etanercept biosimilar provides value over Enbrel.

Court Probes Rationale Of Biosimilars' 180-Day Notice

There was a lot of inside baseball being played at the US Court of Appeals for the Federal Circuit during April 4 oral arguments when Amgen Inc. battled Apotex Inc. over whether Congress intended for it to be mandatory for biosimilar makers to provide 180 days notice of commercial marketing (NCM) to the reference product sponsor (RPS) after the FDA licenses a copycat product.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel